Aspirin 300 mg/day is effective for treating aspirin‐exacerbated respiratory disease

Background Aspirin desensitization ( AD ) treatment at doses of up to 1300 mg/day improves outcomes in aspirin‐exacerbated respiratory disease ( AERD ). The aim of this study was to investigate the efficacy of aspirin 300 mg/day in the treatment of patients with AERD . Methods The study included 40 patients diagnosed in our clinic as AERD that were desensitized and treated with aspirin 300 mg/day between D ecember 2005 and D ecember 2012. Changes from the baseline status were analyzed at 1 year and at 3 years of follow‐up. Results Of the 40 patients included, 24 (60%) were female and median (interquartile range [ IQR ]) age was 45 (40–51) years. Median ( IQR ) duration of AD was 31.5 (10.5–48.5) months. In total, 29 patients continued treatment for at least 1 year and 18 patients for at least 3 years. The annual rate of use of systemic corticosteroid regimens, episodes of sinusitis, and surgery was significantly lower both at 1 year ( P  = 0.002, P  = 0.01, and P  < 0.001, respectively) and at 3 years ( P  = 0.001, P  = 0.03, and P  = 0.002, respectively). Significant improvement was observed in the nasal congestion score ( P  = 0.01) and sense of smell score ( P  = 0.05) at 1 year and in the postnasal drainage score ( P  = 0.01) at 3 years. Conclusion Daily treatment with aspirin 300 mg had beneficial effects in patients with AERD , especially for the control of upper airway disease.